Biotech News
Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
- Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT -
LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced that it will present an...
